Ligand Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Ligand Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Ligand Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Ligand Pharmaceuticals, Inc.

The report provides overview of Ligand Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Ligand Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Ligand Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Ligand Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ligand Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ligand Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ligand Pharmaceuticals, Inc. Snapshot 6

Ligand Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Ligand Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Ligand Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

Ligand Pharmaceuticals, Inc. - Pipeline Products Glance 19

Ligand Pharmaceuticals, Inc. - Late Stage Pipeline Products 19

Pre-Registration Products/Combination Treatment Modalities 19

Phase III Products/Combination Treatment Modalities 20

Ligand Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 21

Phase II Products/Combination Treatment Modalities 21

Phase I Products/Combination Treatment Modalities 22

Ligand Pharmaceuticals, Inc. - Early Stage Pipeline Products 23

Preclinical Products/Combination Treatment Modalities 23

Ligand Pharmaceuticals, Inc. - Drug Profiles 24

lasofoxifene tartrate 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

clopidogrel bisulfate 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

aplindore fumarate 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

pradefovir mesylate 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

MB-07133 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

LGD-6972 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drug to Inhibit JAK3 for Inflammation 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

LG-7455 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

LGD-3437 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

LGD-7501 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

PS-031291 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecule to Antagonize CCR1 for Oncology 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules to Activate Glucokinase for Type 2 Diabetes 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Ligand Pharmaceuticals, Inc. - Pipeline Analysis 40

Ligand Pharmaceuticals, Inc. - Pipeline Products by Target 40

Ligand Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 42

Ligand Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 43

Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 44

Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates 46

Ligand Pharmaceuticals, Inc. - Dormant Projects 51

Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

adipiplon 52

clopidogrel bisulfate 52

LGD-5552 52

managlinat dialanetil 52

NGD-2000-1 53

NGD-91-1 53

NGD-91-2 53

NGD-91-3 53

NGD-94-1 53

NGD-94-4 53

NGD-96-1 53

NGD-97-1 53

Vanilloid Receptor-1 Program 54

Ligand Pharmaceuticals, Inc. - Company Statement 55

Ligand Pharmaceuticals, Inc. - Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Ligand Pharmaceuticals, Inc., Key Information 6

Ligand Pharmaceuticals, Inc., Key Facts 6

Ligand Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Ligand Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Ligand Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Ligand Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Ligand Pharmaceuticals, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

Ligand Pharmaceuticals, Inc. – Out-Licensed Products in Pipeline, 2016 16

Ligand Pharmaceuticals, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 17

Ligand Pharmaceuticals, Inc. – Pre-Registration, 2016 19

Ligand Pharmaceuticals, Inc. – Phase III, 2016 20

Ligand Pharmaceuticals, Inc. – Phase II, 2016 21

Ligand Pharmaceuticals, Inc. – Phase I, 2016 22

Ligand Pharmaceuticals, Inc. – Preclinical, 2016 23

Ligand Pharmaceuticals, Inc. – Pipeline by Target, 2016 40

Ligand Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 42

Ligand Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 43

Ligand Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 44

Ligand Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 46

Ligand Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 51

Ligand Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 52

Ligand Pharmaceuticals, Inc., Subsidiaries 56

List of Figures

List of Figures

Ligand Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

Ligand Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Ligand Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Ligand Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Ligand Pharmaceuticals, Inc. – Out-Licensed Products in Pipeline, 2016 16

Ligand Pharmaceuticals, Inc. – Pipeline by Top 10 Target, 2016 40

Ligand Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 42

Ligand Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 43

Ligand Pharmaceuticals, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 44

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports